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Abstract
Background: This study aims to differentiate human induced pluripotent stem cells (hiPSCs) into oligodendrocyte
precursors and assess their recovery potential in a demyelinated optic chiasm model in rats.
Methodology/Principal Findings: We generated a cell population of oligodendrocyte progenitors from hiPSCs by using
embryoid body formation in a defined medium supplemented with a combination of factors, positive selection and
mechanical enrichment. Real-time polymerase chain reaction and immunofluorescence analyses showed that stage-specific
markers, Olig2, Sox10, NG2, PDGFRa, O4, A2B5, GalC, and MBP were expressed following the differentiation procedure, and
enrichment of the oligodendrocyte lineage. These results are comparable with the expression of stage-specific markers in
human embryonic stem cell-derived oligodendrocyte lineage cells. Transplantation of hiPSC-derived oligodendrocyte
progenitors into the lysolecithin-induced demyelinated optic chiasm of the rat model resulted in recovery from symptoms,
and integration and differentiation into oligodendrocytes were detected by immunohistofluorescence staining against PLP
and MBP, and measurements of the visual evoked potentials.
Conclusions/Significance: These results showed that oligodendrocyte progenitors generated efficiently from hiPSCs can be
used in future biomedical studies once safety issues have been overcome.
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Introduction
Demyelinating diseases such as multiple sclerosis (MS) are
characterized by damage to the myelin sheath surrounding
neurons, causing impaired nerve impulses that lead to a
constellation of neurological symptoms. Recent research on cell
transplantation has yielded new insights into the novel possibilities
of using stem cell-derived oligodendrocytes in graft-based
remyelination therapy to restore action potential conduction.
However, to date, an efficient and reliable cell source has not been
introduced (for review, see [1]. The recent groundbreaking
developments regarding induced pluripotent stem cells (iPSCs)
generated from easily accessible somatic cells [2] appear to offer a
nearly inexhaustible source of transplantable, autologous neural
stem cells (for review, see [3,4]. Many studies have demonstrated
that mouse and human iPSCs are highly morphologically,
molecularly and phenotypically similar to their respective
embryo-derived embryonic stem cell (ESC) counterparts [5,6].
The use of iPSCs also circumvents the ethical issue related to using
ES cells and producing human disease models in vitro (for review,
see [7].
Several studies have reported the functional maturation and
neural and oligodendrocyte differentiation of ESCs in vitro as well
as therapeutic use of ESCs in animal models of demyelinating
diseases and remyelination after spinal cord injury [8–24]. These
studies have suggested that ESC-derived oligodendrocyte
progenitors (OPs) can potentially promote regeneration and
reduce secondary degeneration by protecting and restoring
axons.
To date, there have been two reports of differentiation of OPs
from mouse iPSCs [25,26]. However, there is no report of
differentiation of OPs from human iPSCs (hiPSCs) and their
transplantation into a demyelinating animal model. Based on the
similarity of hiPSCs and human ESCs (hESCs), we hypothesized
that generation and maturation of OPs from hiPSCs in vitro could
be achieved with the same protocol used with hESCs. Therefore,
we applied a previously described protocol for differentiating
hESCs into oligodendrocyte lineage cells [27] to hiPSCs.
Additionally, following transplantation, we investigated the
capacity of the hiPSC-derived OPs to improve demyelinated
optic chiasm in a rat model, which had been induced by
lysolecithin.
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Differentiation and characterization of hiPSCs and hESCs
into OPs and oligodendrocytes
The differentiation procedure and the morphology of cells at
different stages are illustrated in Figure 1. Selective oligodendro-
cyte differentiation from undifferentiated feeder-free hiPSCs (stage
1) was performed by forming EB and culturing the cells in a
GRM/hESC medium containing 4 ng/ml bFGF at a 1:1 ratio.
The EBs were then exposed to GRM in the presence of RA and
EGF for nine days (stage 2). This exposure led to the appearance
of a transparent sphere of cells (Figure 1, B type) and yellow
spheres of cells (Figure 1, A type) that contained oligodendrocyte-
lineage cells. With the removal of RA and continuing the
suspension cultures in GRM supplemented with EGF for 18 days,
the size of the yellow spheres increased. At day 28, yellow-type
free-floating spheres were plated on Matrigel. In the Matrigel
cultures, cells migrated progressively outward from the spheres
and were maintained and proliferated in the same medium. Cells
were passaged (1:2) twice every seven days (day 42, stage 3). At this
step, cells displayed immature oligodendrocyte bipolar and
multipolar morphologies, which were similar to those of OPs.
To evaluate the oligodendrocyte maturation potential of these
cells, induction was used by removing EGF from the medium, and
Figure 1. Differentiation protocol and cellular morphologies during oligodendroglial-lineage cell differentiation. hiPSCs (hiPSC1 and
hiPSC8 lines) and hESCs (Royan H6 line) were differentiated to oligodendrocyte lineage cells during induction of neural-lineage cells with the
preferential selection of oligodendroglial-lineage cells using media components. Morphologies of cells at the related stages are depicted. Two types
of spheres were observed in stage 2: yellow spheres (A), which were plated on Matrigel for the subsequent stages, and transplant spheres (B), which
were removed from cultures. The representative pictures showed hiPSC1 differentiation.
doi:10.1371/journal.pone.0027925.g001
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2) on a PLL/
lam substrate for three weeks. After this treatment, plated cells
adopted an oligodendroglial morphology characterized by multi-
ple branches (stage 4). The same morphological results were
observed for hESCs.
Cells were examined by qRT-PCR at different points of
differentiation for expression of markers typical of oligodendrocyte
development in hiPSCs and hESCs (Figure 2). OCT4 and SOX2,
markers of pluripotency, were down-regulated following induction.
Additionally, we could not detect OCT4-positive cells by
immunofluorescence staining at stages 3 and 4 in the hiPSC-
derived OPs. Expression of the neural markers PAX6 and TUJ1
was up-regulated, and the expression of TUJ1 decreased at stage 4
following additional maturation. The expression levels of PDGFRa
and OLIG2 (OPs markers) were up-regulated during OP induction
(stages 2 and 3) and down-regulated after more differentiation
(stage 4).
We evaluated the OPs (stage 3) and differentiated immature
oligodendrocytes (stage 4) at the cellular level by immunofluores-
cence staining (Figure 3). Random field counting of immunoflu-
Figure 2. Relative gene expression using real-time PCR. Fold changes of expression were reported as log2. For real-time PCR, sampling was
performed at four different stages during the differentiation protocol. Several primers were used for the pluripotent genes (Oct4 and Sox2), the
neural lineage genes (Pax6 and Tuj1), and the oligodendrocyte lineage genes (Olig2 and PDGFRa). Expression of the pluripotent-specific genes
decreased during the differentiation of hiPSC1(A) and hESC (Royan H6 line) (B) lines into oligodendrocytes when compared to stage 1. Expression
levels of Pax6, Tuj1, and PDGFRa increased, but Tuj1 and PDGFRa expression decreased in stage 4. Gene expression levels at different hiPSCs and
hESC-oligodendrocyte lineage cell stages relative to the levels in stage 1 approximate the gene expression levels of derived cells. c: p,0.05, b:
p,0.01, a: p,0.001 vs. hiPSC1 or hESC stage; Error bar: SEM.
doi:10.1371/journal.pone.0027925.g002
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OPs (.90%) expressed related oligodendrocyte lineage markers
(Figure 3) including OLIG2 (94.3762.69%), SOX10 (96.616
0.80%), A2B5 (95.7460.22%) and O4 (96.4661.21%). Immuno-
fluorescence in hiPSC-derived OPs was also positive for NG2
(82.0465.88%) and PDGFRa (80.7264.43%). However, the
number of cells positive for these OP markers significantly
decreased to 52.4166.55% (p,0.05) and 42.8763.19%
(p,0.01) in stage 4, respectively (Figure 3 B, C). The number of
counted cells for each antibody has presented in Table S1.
PDGFRa, A2B5 and NG2 are membrane epitopes typically
expressed in OPs [40,41]. SOX10 is a member of the high-
mobility group domain family of DNA binding proteins expressed
within OPs, yet it is not expressed in neurons or astrocytes [42].
The Olig2 transcription factor is critical for oligodendrocyte and
motor neuron differentiation [43].
Figure 3. Immunofluorescence staining of differentiated oligodendrocyte lineage cells from hiPSCs and hESCs. (A) The representative
pictures of Olig2, Sox10, PDGFRa, NG2, O4, A2B5, GalC, MBP, GFAP, and MAP2 expression in hiPSC1-derived OPs. Oligodendrocyte lineage markers
exhibit high levels of expression in the OP stage, while the astrocyte cell protein GFAP and the neuronal protein MAP2 are minimally expressed (A).
The removal of EGF from the hiPSC1-derived OPs medium results in down-regulation of NG2 and PDGFRa and up-regulation of GalC and MBP, as
shown in (B). The percentage of positive cells at stage 3 and 4 for hiPSC1-derived oligodendrocyte lineage cells and hESC-derived OPs at stage 3 for
some markers (C). (c) p,0.05; (b) p,0.01; (a) p,0.001. Error bar: SEM.
doi:10.1371/journal.pone.0027925.g003
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oligodendrocyte-specific genes such as MBP and GalC increased
(GalC: 7.4962.37% to 73.7565.97%, p,0.01; MBP:
0.3060.15% to 19.5165.56%, p,0.05). MBP is localized to the
major dense lines of myelin and confined to the interior of
oligodendrocytes [44,45]. No significant differences were noted
among the expressions of OLIG2, SOX10, O4, GFAP, and
MAP2 in hiPSC-derived cells in stages 3 and 4 (Figure 3C). O4 is a
surface antigen on immature and mature oligodendrocytes [46].
Importantly, the levels of the astrocyte marker GFAP and the
neuronal marker MAP2 were the same before and after
differentiation [GFAP (1.0760.42%) and MAP2 (5.2661.17%)]
(Figure 3C). Therefore, the oligodendrocyte lineage was enriched
relative to neurons or astrocytes. Additionally, this in vitro protocol
for oligodendrocyte differentiation of hESCs resulted in efficient
induction of oligodendrocytes and their progenitors from hiPSCs.
Similar results in expression were observed in hESCs (Royan
H6 line, Figure 3C) and hiPSC8 in RNA and protein levels
(Figures S1 and S2). Therefore, we continued our transplantation
experiments with hiPSC1-derived OPs.
Transplantation into the optic chiasm rat model of
demyelination
The amounts of demyelination and remyelination were
histologically evaluated using Luxol fast blue myelin-specific
staining one, five and nine weeks post-lesion. Extensive demyelin-
ation was demonstrated one week post-lesion (Figure 4A). Four
and eight weeks after transplantation of hiPSC1-derived OPs an
obvious remyelination was seen, while less remyelination was seen
in control chiasms (Figure 4B and C).
Improvement in remyelination of the optic chiasm and nerves
was functionally evaluated using VEP recording from the skull.
Changes in the P1 wave-latency was assessed in the control,
vehicle and cell transplanted animals (Figure 4D). While low levels
of endogenous recovery of P1-latency were observed in the control
and vehicle-treated animals eight weeks post-lesion, cell grafting
reduced the elevated latency relative to the control by one week
post-transplantation, and this reduction persisted until eight weeks
post-transplantation.
Eight weeks after transplantation, tracing of DiI-labeled cells
showed that the transplanted cells survived and integrated within
the chiasm (Figure 5). Double labeling for DiI and PLP, MBP,
GFAP, or MAP2 showed that the majority of the grafted cells were
PLP+ and/or MBP+, which demonstrated differentiation of
hiPSC1-derived OPs into mature oligodendrocytes in vivo and
confirmed remyelination by the transplanted cells (Figure 5).
Additionally, a few of the transplanted cells were GFAP+ or
MAP2+, which indicated non-astroglial and non-neuronal differ-
entiation of the grafted cells in vivo. DiI-unlabeled transplanted
cells were used as negative control, eight weeks post-cell
transplantation (Figure S3).
Additionally, we did not observe tumor, teratoma or non-
neuronal tissue formation in the transplant recipients at four or
eight weeks following hiPSC1-derived OPs transplantation.
Discussion
Several studies have demonstrated generation of oligodendro-
cyte lineage cells from hESCs with different efficiencies [14–23].
Based on these reports, we developed a protocol and applied it to
differentiate hiPSC into an oligodendrocyte lineage. Our data
showed that our protocol efficiently generated hiPSC-derived OPs
in vitro. Additionally, the transplantation of these OPs seven days
after lysolecithin induced demyelination to the optic chiasm of the
rat models resulted in significant functional recovery compared to
the control and vehicle groups.
The method used to differentiate hiPSCs toward an oligoden-
drocytic cell lineage was based on sequential induction at proper
time intervals by introducing appropriate induction and growth
factors. This method has previously been used to generate OPs
from hESC (Hatch et al., 2009).
Our hiPSCs were induced into an oligodendrocyte lineage by
EB formation following the plating of yellow spheres that were
generated in the presence of RA in GRM. Bipolar and
proliferating hiPSC-derived OPs appeared following migration
of cells from yellow spheres and became complex ramified
oligodendrocytes after growth factors were withdrawn. Thyroid
hormone was needed to ensure oligodendrocyte survival and to
initiate the differentiation of OPs into mature oligodendrocytes
[47].
Moreover, our quantitative real-time PCR and immunostaining
data has shown that hiPSCs share similarities in gene expression
patterns with hESCs during differentiation to oligodendrocytes.
The percentage of antigen-expressing cells measured by immuno-
fluorescence staining exhibited no significant difference between
hiPSC-derived OPs and hESC-derived OPs. OP specific markers
such as OLIG2, A2B5, SOX10, NG2, PDGFRa, and O4 were
expressed in the majority of cells. However, later oligodendrocyte
markers, such as GalC and MBP, were expressed in few cells.
Contamination with other neural lineage types was low, as few of
the cells were positive for GFAP and MAP2 at the OP step.
Additionally, the expression of pluripotent genes was strongly
down-regulated. We continued to culture adherent hiPSC-derived
OPs by trypsinization during several passages (results not shown)
using a method similar to one previously described for expandable
hESC-derived OPs [48]. These findings demonstrated that a
population of pure hiPSC-derived OPs was generated in this study
as well as a population of pure hESC-derived OPs.
Furthermore, developmental studies have demonstrated that
GalC (70%) and MBP (20%) begin to express in both immature
oligodendrocytes and mature oligodendrocytes [49,50]. These
results indicate that hiPSC-derived OPs can differentiate into
more mature oligodendrocytes, but our conditions were insuffi-
cient to achieve full maturation in vitro, which may require other
parameters such as cell contact with other types of CNS cells.
This study has assessed the therapeutic effects of transplanted
hiPSC-derived OPs in toxically-induced demyelination of the rat
chiasm. The production of animal models with CNS white matter
locally demyelinated by toxic materials such as lysolecithin
provides a good tool for assessing the therapeutic effects of
transplanted oligodendrocyte cells. Lysolecithin in applied con-
centration is toxic and particularly affects myelin-producing cells
[51,52] and can therefore be used to produce local, acute
demyelination in the CNS [34]. Cells were transplanted one week
after and in the same manner as the lysolecithin injection. Our
histology results demonstrated that demyelination occurred in the
chiasm one week after the lysolecithin injection. Luxol fast blue
staining of chiasm sections four and/or eight weeks after hiPSC-
derived OPs transplantation showed increased staining and
remyelinating axons. The engrafted OPs survived, migrated and
integrated into the host tissue at week’s post-cell transplantation.
Functional changes to the optic nerve were recorded with VEP
measurements. It was also shown that hiPSC-derived OPs
promoted recovery in transplanted rats compared to vehicle-
injected and control rats. This improvement was observed
particularly in the first week after cell transplantation, which
indicates the short-term effectiveness of this transplantation.
Immunohistofluorescence analysis of the grafts indicated that the
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MBP protein, demonstrating that OPs derived from hiPSCs
completed differentiation after transplantation to the demyelinated
chiasm. A few of the cells displayed the astrocyte marker, GFAP in
the chiasm of the transplanted rats. It has been shown that
transplanted hESC-derived OPs improve the recovery of spinal
cord injury in demyelination models [14–22]. Recently, it was
shown that mouse iPSC-OPs could also become functional
remyelinating oligodendrocytes, as demonstrated in vitro by co-
culture of these cells with neurons and in vivo after implantation in
the demyelinated corpus callosum of cuprizone-treated mice [26].
Additionally, it was reported that axonal loss in eyes that received
concurrent inflammatory activated OPs was lower than axonal loss
in control eyes in a glaucoma model [53].
On the other hand, in addition to their differentiation into
mature oligodendrocytes following transplantation, hiPSC-derived
OPs may also have indirect effects on the host tissue through
secretion of anti-inflammatory and tropic molecules. hESC-
derived OPs have been shown to express several neurotrophic
factors that result in neuronal survival and the regeneration of
damaged neurons [16]. Also, the trophic effect of transplanted NPs
enhanced myelin regeneration of the host OPs in a chronic
cuprizone-induced demyelination model in aged mice [54].
Moreover, we could not identify OCT4-positive cells at the OP
generation stage. We did not observe teratoma formation after
eight weeks, indicating that no undifferentiated iPSCs were
present after our oligodendrocyte differentiation procedure.
To our knowledge, this is the first report on the differentiation of
hiPSCs into oligodendrocyte-lineage cells and their transplantation
in an animal model. These hiPSC-derived OPs improved myelin
repair in lysolecithin-induced demyelinated-rat optic chiasm which
reveal the possible application of these patient specific cells in
future regenerative biomedicine. However, several issues remain
to be solved before hiPSC-derived cells can be safely applied in
Figure 4. Histological and behavioral assessments following demyelinated chiasm injury and cell transplantation. (A) A longitudinal
section of a demyelinated region stained with Luxol fast blue at the first week post-lesion. (B) Representative Luxol fast blue staining of chiasm
sections nine weeks’ post-lesion in vehicle group. (C) Myelin repair in the optic chiasm using Luxol fast blue in representative sections eight weeks
post-transplantation with hiPSC1-derived OPs. (D) Functional evaluation of the optic apparatus using VEP recording in animal models. Changes in the
baseline latency of the P1 wave following local injection of hiPSC1-derived OPs in the transplant group are shown along with those of the medium
(vehicle) and control groups. The arrow shows the time of cell or medium injection. b: p,0.01 and a: p,0.001 vs. week 1, c: p,0.01 vs. vehicle treated
and control groups in the same week. Error bar: SEM. Tx: transplantation. PL: post-lesion.
doi:10.1371/journal.pone.0027925.g004
Transplantation of hiPSCs-Derived OPs
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27925clinical settings (for reviews, see [3,4]). For example, recently it has
reported that transplantation of undifferentiated iPSCs which
derived by either retroviral approach or a episomal approach
showed T-cell-dependent immune response in recipient syngeneic
mice due to the abnormal expression of antigens following genetic
manipulation [55,56]. Improvements in the production of safe and
non-immunogenic hiPSCs will increase the number of applications
of iPSC derivatives.
Materials and Methods
Pluripotent stem cell culture and differentiation into
oligodendrocyte lineage cells
The hiPSC line Royan hiPSC1 and hiPSC8 [28] at passages
29–47 was used in these experiments. Cells were expanded and
passaged under feeder-free culture conditions in a hESC medium
that contained 100 ng/ml basic fibroblast growth factor (bFGF,
Royan Institute) using a previously described technique [29]. The
medium was changed every other day until day 7. The
differentiation procedure (outlined in Figure 1) was divided into
four stages, as described in (Hatch et al., 2009). The hiPSC
colonies were exposed to an enzymatic mixture that contained
1 mg/ml collagenase IV (Invitrogen, 17104-019) and 2 mg/ml
dispase (Invitrogen, 17105-041) for 7 min at 37uC. The enzymes
were then removed, and the colonies were rinsed with Dulbecco’s
phosphate-buffered saline (D-PBS, Invitrogen, 14190-144). Cell
clusters were scraped from the dish after the addition of hESC
medium/glial restriction medium (GRM) at a 1:1 ratio and
collected in low-attachment bacteriological dishes (Falcon,
351029). A total of 4 ng/ml bFGF was added to the culture
media, and cells were then transferred to an incubator. The GRM
consisted of DMEM/F12 (Invitrogen, 21331-020), 2% B27
supplement (Invitrogen, 17504-044), 2 mM L-glutamine (Invitro-
gen, 25030-024), 10 mg/ml insulin (Sigma-Aldrich, I1882), 10 mg/
ml putrescine (Sigma-Aldrich, P6024), 63 ng/ml progesterone
(Sigma-Aldrich, P6149), 50 ng/ml sodium selenite (Sigma-Al-
drich, S9133), 50 mg/ml holo-transferrin (Sigma-Aldrich, T1408),
and 40 ng/ml triiodothyronine (T3; Sigma-Aldrich, T6397). The
following day, cell clusters were collected and transferred to hESC
medium/GRM containing 4 ng/ml bFGF, 20 ng/ml human
epidermal growth factor (EGF; Sigma-Aldrich, E9644) and
10 mM all-trans-retinoic acid (RA; Sigma-Aldrich, R2625). Over
Figure 5. Immunofluorescence staining of transplanted cells. The hiPSC1-derived OPs were labeled with DiI before transplantation into
chiasms and immunostained with antibodies against PLP, MBP, GFAP, or MAP2 eight weeks after transplantation. The majority of DiI-labeled cells
showed PLP and/or MBP reactivity, and a few of them were GFAP+ and/or MAP2+.
doi:10.1371/journal.pone.0027925.g005
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containing 20 ng/ml EGF and 10 mM RA. After eight days, RA
was omitted from the media, and floating clusters were cultured
for 18 days during which the medium was changed every other
day. At day 28 of the differentiation protocol, yellow clusters were
cultured on matrigel- (Sigma-Aldrich, E1270) coated 6 cm tissue
culture dishes in the same medium. Clusters adhered to the dishes,
and cells were dislodged one week later using 0.05% trypsin/
EDTA (Invitrogen, 25300) for 3 min at 37uC. Trypsin was
neutralized with DMEM/F12 containing 10% fetal bovine serum
(FBS; Hyclone, SH30070) and centrifuged, and the cell pellet was
resuspended in GRM plus 20 ng/ml EGF and reseeded on
matrigel-coated dishes for seven days. Cells underwent weekly
passaging.
OPs were more differentiated on poly-L-Lysine (Sigma-Aldrich,
P4707)/laminin-coated plates (Sigma-Aldrich, L2020) (PLL/lam)
in the absence of EGF over a three-week period. In some of the
experiments, the Royan H6 hESC line [30] at passages 102–127
was used as a control group.
Real-time reverse transcription PCR
At each stage, cells were collected, and the total RNA was
extracted using TRIzol reagent (Invitrogen, 15596-018). DNA was
degraded with the use of the DNase I, RNase-free kit (Fermentas,
EN0521), whereas RNA was protected using RiboLockTM RNase
Inhibitor (Fermentas, E00381). cDNA was synthesized using a
RevertAidTM H Minus First Strand cDNA Synthesis kit
(Fermentas, K1632). Relative gene expression analysis was
performed with real-time PCR. The expression of several genes,
including POU5F1 (Oct4), Sox2, Pax-6, Tuj1, Olig2 PDGFRa
and a housekeeping gene, b-actin, were analyzed at four stages of
the oligodendrocyte differentiation procedure. Real-time PCR
used specific primers (Table S2), a 96-well optical reaction plate
and the 7500 Real Time PCR system (Applied Biosystems). In
each PCR reaction, 1X Power SYBRH Green PCR Master Mix
(ABI PRISM, 4368702) was mixed with 12 ng cDNA and specific
primers in a total volume of 20 ml. Thermal conditions were the
same for all genes, and the annealing temperature was 60uC.
The comparative Ct method, 2
2DDCt, was used for relative gene
expression analysis [31]. All Ct values calculated from the target
genes were normalized to b-actin and calibrated using calculations
from the undifferentiated pluripotent cells from stage 1. In each
experiment, there were at least three independent replicates of
each stage, and each replicate included two identical samples.
Immunofluorescence staining
For immunofluorescence staining, cultured cells were washed
with washing buffer (phosphate-buffered saline (PBS) with 0.05%
tween-20 (Sigma-Aldrich, P7949), pH 7.4) and fixed with 4%
paraformaldehyde (Sigma-Aldrich, P6148) in PBS for 10 min. If
necessary, cells were then permeabilized with 0.5% Triton X-100
(Sigma-Aldrich, T8532) for 15 min. Cells were twice washed and
blocked in 10% secondary antibody host serum in washing buffer
for 30 min at 37uC. Cells were incubated overnight at 4uC with
primary antibodies (Table S3) diluted in washing buffer. Cells were
washed three times (5 min each) and then incubated with
fluorescence-labeled secondary antibodies in washing buffer at
room temperature and rinsed three times (5 min each). For
negative controls, only the secondary antibody was used (results
not shown). Either the fluorescent dye propidium iodide (PI; Fluka,
81845) or 49,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich,
D-8417) was used for staining nuclei.
Images were obtained on an Olympus IX71 fluorescence
microscope with a DP72 digital camera and captured by analySIS
LS Starter version 3.2. For cell counting, 10 random images were
prepared from different sites on each plate, and fluorescent-stained
cells of each marker were counted in each image. The experiment
was performed on at least three independent cell cultures for each
antibody. The percentage of positive cells was determined as the
ratio of positive cells to the total number of counted cells (stained
with PI or DAPI) in each experiment.
Implantation of hiPSC-derived OPs in lysolecithin-
induced demyelinated rat chiasm
To evaluate the capacity of hiPSC-derived OPs to restore
myelination in vivo, cells were implanted in the demyelinated optic
chiasm of lysolecithin-injected rat models.
Ethics statement. All animal use procedures were in strict
accordance with the approval of the Royan Institutional Review
Board and Institutional Ethical Committee under the approval ID
of J/90/1397.
Animals. Adult male Sprague Dawley rats (240–280 g) were
obtained from Razi Institute (Karaj, Iran). Rats were maintained
in temperature-controlled rooms with a 12/12 h light/dark cycle
and 50–55% humidity and had free access to food and water.
Preparation of cells for transplantation. For identification
after transplantation, the cells were prelabeled with the plasma
membrane marker, red fluorescence-CellTracker CM-DiI (chloro-
methyl benzyl-amide derivatives of 1,1-dioctadecyl-3,3,39,39
tetramethylindocarbocyanine perchlorate; Invitrogen, C7001),
which allowed in vivo identification of grafted cells. Cells were
incubated in 5 mg/ml CM-DiI in GRM medium for 20 min in the
incubator. Cells were then washed three times (365 min) in D-
PBS (Invitrogen, 14190-144). The viability of cells before
transplantation was determined by Trypan blue exclusion dye
assay to be greater than 95%.
Surgical procedure and cell transplantation. The animals
were anesthetized with intraperitoneal (i.p.) injections of 50 mg/kg
ketamine and 5 mg/kg xylazine and placed in a stereotaxic
instrument. A 30-gauge stainless steel needle was used to inject
lysolecithin into the chiasm (anterior-posterior: 0.1 mm from the
bregma, lateral: 0 mm and vertical: 4.5 mm from the dura) [32].
All animals were administered 2 ml of 1% lysolecithin (Sigma-
Aldrich, L1381) at day zero.
This treatment leads to demyelination of axons after one week.
However, spontaneous remyelination will occur over longer
durations due to endogenous OPs recruited from the adjacent
tissues [33–35]. Therefore, one week after lysolecithin adminis-
tration, rats were divided randomly into three groups: the cell-
transplanted group (n=8) received 200,000 hiPSC-derived OPs in
2 ml medium; the vehicle-transplanted group (n=8) received 2 ml
medium; and a control group (n=8) received no cells and no
vehicle. Cells were transplanted into the chiasm using a 25 ml
Hamilton syringe connected to a 30 gauge needle. A microinjec-
tion system (Stoelting, Illinois, USA) infused the suspension at a
rate of 0.5 ml/minute. After grafting, the needle remained in place
for 1 minute to minimize cell reflux into the needle track. The
animals were then housed in standard rat cages at a temperature
of 27uC. The rats were immune-suppressed by addition of
210 mg/l, cyclosporine-A (Sandimmune, Novartis Pharmaceuti-
cals, East Hanover, NJ, USA) to the drinking water two days
before cell transplantation [36,37]. The animals then remained on
the same immunosuppressant throughout the experiment. Serum
levels of cyclosporine were measured in a random sample of
animals at termination and the average concentration was
1750636 ng/ml (n=2, mean6SEM).
Visual evoked potential (VEP) recording. Functional
changes in the optic nerve were electrophysiologically studied
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5th and 9th weeks post-lesion in all groups. VEP can provide
important diagnostic information regarding the functional
integrity of the visual system [38]. VEP recording was
performed using a previously described technique [35]. Briefly,
two stainless steel screws were placed into the skull to serve as
electrodes. The dura was kept intact to minimize cortical damage.
The ‘‘reference’’ electrode was placed 5 mm anterior to the
bregma and 1.5 mm right of midline, and the ‘‘record’’ electrode
was placed 7 mm caudal to the bregma and 3 mm right of
midline. Light stimulation was delivered by a general evoked
response stimulator (WSI, Iran) 300 times at a frequency of
0.5 Hz. Responses were amplified using an amplifier (Iso-80, UK).
The amplified waveforms were averaged. In each VEP recording,
the latencies between the light flash and the first positive peak were
studied.
Histochemical and immunohistofluorescence analyses.
To study the extent of demyelination, the animals were sacrificed
using a lethal dose of anesthesia one week after lysolecithin
injection and five and nine weeks post-lesion in cell transplanted
and vehicle treated groups (n=3 per group). The chiasms were
immediately stored and post-fixed in 4% paraformaldehyde for
24 h. Some chiasms were processed and embedded in paraffin.
Slices were stained with Luxol fast blue to stain myelin and nuclei
were counterstained with cresyl violet. Tumor formation in the
transplanted animals was assessed by H&E staining.
To follow-up the fate of DiI-labeled transplanted cells, after
fixation in cryoprotected 30% sucrose in PBS at 4uC for 24 h in a
cryostat, some chiasms (n=3 per group) were processed for
immunohistofluorescence analysis of the cell implants. Tissue was
frozen in Jung tissue freezing medium (Leica Microsystems) at
230uC and sectioned with a cryotome into pieces 8 mm thick
(Leica Microsystems, CM 1850). The sections were permeabilized
with 0.04% Triton X-100 and blocked with 10% normal goat
serum and 0.5% BSA (Sigma-Aldrich, A3311) in PBS for 1 h.
Primary antibodies against PLP, MBP, GFAP, MAP2 (Table S3)
were applied overnight at room temperature. Sections were
washed, and the appropriate secondary antibodies, which were
conjugated with fluorescent dye (Table S3), were applied for 1 h at
37uC. Sections were washed and counterstained with the nuclear
dye DAPI. Each protein was evaluated in three chiasms. Images
were obtained on an Olympus BX51 fluorescence microscope with
a DP72 digital camera and captured by analySIS LS Starter
version 3.2.
Statistical analysis
The data are expressed as mean 6 SEM. A difference between
groups was considered statistically significant if p,0.05. For
immunofluorescence staining, an unpaired, two-tailed t-test was
used to assess statistically significant differences. For qRT-PCR,
randomization tests using REST 2009 V2.0.13 software were
applied to indicate statistically significant differences between stage
1 and the remaining stages [39]. All quantitative data and any
significant differences in the latency of the VEPs of each group
were tested using a mixed-model ANOVA with a repeated factor
(time) and a non-repeated factor (group). One-way ANOVA
followed by post-test LSD was performed for each group.
Supporting Information
Figure S1 Relative gene expression using real-time PCR
for hiPSC8 oligodendroglial-lineage cell differentiation.
Log2 changes in expression are reported. In real-time PCR,
sampling was done in four different stages during the differenti-
ation protocol. The primers of OCT4 and SOX2 were used for
pluripotency, TUJ1 for neural lineage, and PDGFRa for
oligodendrocyte lineage differentiation. Obviously, pluripotent
specific genes decreased during the differentiation of hiPSC8 to
oligodendrocyte when compared to stage 1. The expression levels
of PDGFRa were increased; however its expression deceased in
stage 4. b: p,0.01, a: p,0.001; Error bar: SEM.
(TIF)
Figure S2 Immunofluorescence staining of differentiat-
ed oligodendrocyte lineage cells from hiPSC8. (A) The
representative pictures of SOX10, PDGFRa, NG2, O4, A2B5,
GalC, GFAP, and MAP2 expression in hiPSC8-OPs. Oligoden-
drocyte lineage markers showed high levels of expression in the
OP stage whereas, the astrocyte cell protein, GFAP and neuronal
protein MAP2 were minimally expressed (A). The down-
regulation of NG2 (p,0.05) and PDGFRa (p,0.05) and up-
regulation of GalC (p,0.05) as shown in (B) were observed
following removal of EGF. The percentage of positive cells at stage
3 for some markers compared with expression in stage 4 (C). (c)
p,0.05. Error bar: SEM. Scale bars in part (A) are 100 mm.
(TIF)
Figure S3 Negative control for DiI labeling. DiI unlabeled
transplanted cells were used as negative control, 9 weeks post
lesioning.
(TIF)
Table S1 The number of counted cells counterstained
with DAPI or PI in different groups.
(DOC)
Table S2 List of primers used for Real-Time PCR
analysis.
(DOC)
Table S3 List of antibodies used in this study.
(DOC)
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